Kenison Michael R. 4
4 · Proto Labs Inc · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
Proto Labs (PRLB) COO Michael R. Kenison Sells Shares, Exercises Options
What Happened
- Michael R. Kenison, Chief Operations Officer of Proto Labs (PRLB), exercised stock-derived awards and sold common shares on May 11–12, 2026. The filing shows exercises/acquisitions totaling 14,960 shares at aggregate reported exercise costs of about $617,368 (individual exercises at $33.84, $33.52, $39.61 and $59.40). Concurrently, Kenison sold 23,463 shares in open-market/private-sale transactions for a total of approximately $1,636,166 (sales priced between about $67.06 and $70.57).
Key Details
- Transaction dates: May 11–12, 2026 (Form 4 filed May 13, 2026). Filing appears timely.
- Exercises (code M): 3,756 @ $33.84, 3,677 @ $33.52 (May 11); 1,928 @ $33.84, 1,557 @ $39.61, 4,042 @ $59.40 (May 12).
- Sales (code S): total 23,463 shares sold — 7,433; 1,613; 4,198; 3,576; 6,643 — weighted average sale prices reported per footnotes; total proceeds ≈ $1.636M.
- Shares owned after transaction: Not reported in this Form 4.
- Notable footnotes: F1 — the shares were acquired and sold pursuant to a 10b5-1 trading plan adopted Aug 15, 2025. F2–F6 — provide weighted-average sale prices and price ranges; the filer will supply per-price breakdown on request. Other footnotes in the filing reference vesting schedules for awards but do not change these transactions.
- Transaction codes explained: M = exercise/conversion of derivative (options); S = open-market/private sale.
Context
- The filing shows exercises and same-period sales, consistent with exercising stock awards and selling shares (often done to cover exercise costs, tax obligations, or per a pre-established trading plan). Because the sales are executed under a disclosed 10b5-1 plan, they were pre-planned trades rather than spontaneous open-market sales. This form is factual disclosure of the insider’s actions and does not by itself indicate the insider’s view on the company’s prospects.
Insider Transaction Report
Form 4
Proto Labs IncPRLB
Kenison Michael R.
Chief Operations Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-05-11$33.84/sh+3,756$127,103→ 30,942 total - Exercise/Conversion
Common Stock
[F1]2026-05-11$33.52/sh+3,677$123,253→ 34,619 total - Sale
Common Stock
[F1][F2]2026-05-11$70.26/sh−7,433$522,251→ 27,186 total - Exercise/Conversion
Common Stock
2026-05-12$33.84/sh+1,928$65,244→ 29,114 total - Exercise/Conversion
Common Stock
2026-05-12$39.61/sh+1,557$61,673→ 30,671 total - Exercise/Conversion
Common Stock
2026-05-12$59.40/sh+4,042$240,095→ 34,713 total - Sale
Common Stock
[F3]2026-05-12$67.58/sh−1,613$109,008→ 33,100 total - Sale
Common Stock
[F4]2026-05-12$68.70/sh−4,198$288,390→ 28,902 total - Sale
Common Stock
[F5]2026-05-12$69.78/sh−3,576$249,542→ 25,326 total - Sale
Common Stock
[F6]2026-05-12$70.30/sh−6,643$466,975→ 18,683 total - Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F7]2026-05-11−3,756→ 3,856 totalExercise: $33.84Exp: 2033-02-14→ Common Stock (3,756 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F1][F8]2026-05-11−3,677→ 3,778 totalExercise: $33.52Exp: 2034-02-13→ Common Stock (3,677 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F7]2026-05-12−1,928→ 1,928 totalExercise: $33.84Exp: 2033-02-14→ Common Stock (1,928 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F9]2026-05-12−1,557→ 4,674 totalExercise: $39.61Exp: 2035-02-25→ Common Stock (1,557 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
[F10]2026-05-12−4,042→ 0 totalExercise: $59.40Exp: 2032-02-13→ Common Stock (4,042 underlying)
Footnotes (10)
- [F1]These shares were acquired and sold pursuant to Reporting Person's 10b5-1 plan adopted August 15, 2025.
- [F10]25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested.
- [F2]Reflects the weighted average price of 7,433 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 11, 2026, with sale prices ranging from $70.00 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Reflects the weighted average price of 1,613 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $67.06 to $68.05 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Reflects the weighted average price of 4,198 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $68.10 to $69.0425 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]Reflects the weighted average price of 3,576 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $69.13 to $70.1181 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Reflects the weighted average price of 6,643 shares of common stock of Proto Labs Inc. sold by the reporting person in multiple transactions on May 12, 2026, with sale prices ranging from $70.13 to $70.57 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F7]25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested.
- [F8]25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
- [F9]25% of shares subject to the award will vest on February 25, 2026, and on each February 25th thereafter until all shares subject to the award are fully vested.
Signature
/s/ W. Morgan Burns, Attorney-in-Fact|2026-05-13